Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study - Safety and Efficacy of Dalbavancin in Early Outpatient Treatment of Erysipelas and Limited Cellulitis
2025-524877-18-00Phase 4Authorised
- Sponsor
- Salzburger Landeskliniken
- Start
- Apr 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI), erysipelas and cellulitis, sponsored by Salzburger Landeskliniken. Primary endpoints: Early discharge due to sufficient infection control, Incidence of adverse events during therapy and 1 more. Planned start Apr 2026; status: authorised.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)erysipelascellulitis
Beyond the preview
Go deeper on 2025-524877-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524877-18-00.